Recent Updates
Recently added Catalysts

Moderate to Severe Atopic Dermatitis: one US-listed biotech with a clinical-stage programme

Immunology & InflammationUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$2.6Buniverse median $1.20B
Allocated capital$1.3B$2.6B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank130/299crowding rank 147

Moderate to Severe Atopic Dermatitis is uncontested. Nektar Therapeutics (NKTR) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Rezpegaldesleukin in phase 3.

There is no public comparable to price it against. NKTR spreads its $2.6B market cap across 2 indications, so $1.3B of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$1.3B of allocated capital sits in Moderate to Severe Atopic Dermatitis, ranking it 130th of 299 indications by the money committed to it.

Companies developing drugs for Moderate to Severe Atopic Dermatitis 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
NKTRNektar TherapeuticsRezpegaldesleukinPhase 33$2.6BNo2 1 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Moderate to Severe Atopic Dermatitis counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Moderate to Severe Atopic Dermatitis has one competitor and a median of $2.6B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Eosinophilic Esophagitis2 companies · $1.2B · median $610MOrphan cornerPruritus2 companies · $1.2B · median $1.6BConcentrated betAutoimmune Pulmonary Alveolar Proteinosis1 company · $1.1B · median $1.1BUncontestedChronic Spontaneous Urticaria1 company · $1.0B · median $3.1BUncontestedImmunoglobulin A Nephropathy1 company · $1.6B · median $6.3BUncontestedANCA-associated Vasculitis2 companies · $1.7B · median $3.3BConcentrated betFocal Segmental Glomerulosclerosis2 companies · $1.7B · median $3.3BConcentrated betPeanut Allergy1 company · $861M · median $861MUncontested

Moderate to Severe Atopic Dermatitis pipeline questions

Which biotech companies are developing drugs for Moderate to Severe Atopic Dermatitis?

Nektar Therapeutics (NKTR, Rezpegaldesleukin, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Moderate to Severe Atopic Dermatitis.

How advanced is the Moderate to Severe Atopic Dermatitis pipeline?

Of the 1 clinical-stage programme in Moderate to Severe Atopic Dermatitis, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Moderate to Severe Atopic Dermatitis?

No. NKTR is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Moderate to Severe Atopic Dermatitis, which is why the indication is classified as uncontested.

When is the next Moderate to Severe Atopic Dermatitis catalyst?

The next dated catalyst in Moderate to Severe Atopic Dermatitis is NKTR on 1 Oct 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map